{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T10:32:31Z","timestamp":1769941951448,"version":"3.49.0"},"reference-count":43,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2022,10,28]],"date-time":"2022-10-28T00:00:00Z","timestamp":1666915200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Deutsche Forschungsgemeinschaft (DFG)","award":["DVK: KA 5558\/1-1"],"award-info":[{"award-number":["DVK: KA 5558\/1-1"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceuticals"],"abstract":"<jats:p>New antithrombotic drugs are needed to combat thrombosis, a dangerous pathology that causes myocardial infarction and ischemic stroke. In this respect, thrombin (FIIa) represents an important drug target. We herein report the synthesis and biological activity of a series of 1H-pyrazol-5-amine-based thrombin inhibitors with a serine-trapping mechanism of action. Among synthesized compounds, flexible acylated 1H-pyrazol-5-amines 24e, 34a, and 34b were identified as potent 16\u201380 nM thrombin inhibitors, which showed practically no off-targeting effect against other physiologically relevant serine proteases. To prove that synthesized compounds are covalent thrombin inhibitors, the most potent derivative 24e (FIIa IC50 = 16 nM) was studied in a mass-shift assay, where it has been shown that 24e transfers its acyl moiety (pivaloyl) to the catalytic Ser195 of thrombin. Performed herein docking studies also confirmed the covalent mechanism of thrombin inhibition by synthesized compounds. Acylated aminopyrazoles found during this study showed only limited effects on plasma coagulation in activated partial thrombin time (aPTT) and prothrombin time (PT) in vitro assays. However, such thrombin inhibitors are expected to have virtually no effect on bleeding time and can be used as a starting point for developing a safer alternative to traditional non-covalent anticoagulants.<\/jats:p>","DOI":"10.3390\/ph15111340","type":"journal-article","created":{"date-parts":[[2022,10,30]],"date-time":"2022-10-30T09:01:42Z","timestamp":1667120502000},"page":"1340","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Pyrazole-Based Thrombin Inhibitors with a Serine-Trapping Mechanism of Action: Synthesis and Biological Activity"],"prefix":"10.3390","volume":"15","author":[{"given":"Calvin","family":"Dunker","sequence":"first","affiliation":[{"name":"Institute of Pharmaceutical and Medicinal Chemistry, University of M\u00fcnster, 48149 M\u00fcnster, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lukas","family":"Imberg","sequence":"additional","affiliation":[{"name":"Institute of Pharmaceutical and Medicinal Chemistry, University of M\u00fcnster, 48149 M\u00fcnster, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alena I.","family":"Siutkina","sequence":"additional","affiliation":[{"name":"Institute of Pharmaceutical and Medicinal Chemistry, University of M\u00fcnster, 48149 M\u00fcnster, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catharina","family":"Erbacher","sequence":"additional","affiliation":[{"name":"Institute of Inorganic and Analytical Chemistry, University of M\u00fcnster, 48149 M\u00fcnster, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6709-3673","authenticated-orcid":false,"given":"Constantin G.","family":"Daniliuc","sequence":"additional","affiliation":[{"name":"Institute for Organic Chemistry, University of M\u00fcnster, 48149 M\u00fcnster, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Uwe","family":"Karst","sequence":"additional","affiliation":[{"name":"Institute of Inorganic and Analytical Chemistry, University of M\u00fcnster, 48149 M\u00fcnster, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2717-5364","authenticated-orcid":false,"given":"Dmitrii V.","family":"Kalinin","sequence":"additional","affiliation":[{"name":"Institute of Pharmaceutical and Medicinal Chemistry, University of M\u00fcnster, 48149 M\u00fcnster, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2022,10,28]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1038\/nm.2515","article-title":"Arterial thrombosis-insidious, unpredictable and deadly","volume":"17","author":"Jackson","year":"2011","journal-title":"Nat. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"S495","DOI":"10.1016\/j.amepre.2009.12.017","article-title":"Venous thromboembolism: A public health concern","volume":"38","author":"Beckman","year":"2010","journal-title":"Am. J. Prev. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1161\/CIRCRESAHA.115.306841","article-title":"Global Burden of Thrombosis: Epidemiologic Aspects","volume":"118","author":"Wendelboe","year":"2016","journal-title":"Circ. Res."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1160\/TH07-03-0183","article-title":"In-Vitro profile and ex-vivo anticoagulant activity of the direct thrombin inhibitor dabigatran and its orally active prodrug, dabigatran etexilate","volume":"98","author":"Wienen","year":"2007","journal-title":"Thromb. Haemost."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/1477-9560-11-11","article-title":"Laboratory assessment of rivaroxaban: A review","volume":"11","author":"Samama","year":"2013","journal-title":"Thromb. J."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1007\/s00392-017-1098-x","article-title":"Comparative risk of major bleeding with new oral anticoagulants (NOACs) and phenprocoumon in patients with atrial fibrillation: A post-marketing surveillance study","volume":"106","author":"Hohnloser","year":"2017","journal-title":"Clin. Res. Cardiol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1021\/acs.jmedchem.9b01060","article-title":"Fibrinolysis Inhibitors: Potential Drugs for the Treatment and Prevention of Bleeding","volume":"63","author":"Steinmetzer","year":"2020","journal-title":"J. Med. Chem."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"112753","DOI":"10.1016\/j.ejmech.2020.112753","article-title":"Factor XII\/XIIa inhibitors: Their discovery, development, and potential indications","volume":"208","author":"Davoine","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1080\/13543776.2021.1945580","article-title":"Factor XII(a) inhibitors: A review of the patent literature","volume":"31","author":"Kalinin","year":"2021","journal-title":"Expert Opin. Ther. Pat."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Tashchilova, A., Podoplelova, N., Sulimov, A., Kutov, D., Ilin, I., Panteleev, M., Shikhaliev, K., Medvedeva, S., Novichikhina, N., and Potapov, A. (2022). New Blood Coagulation Factor XIIa Inhibitors: Molecular Modeling, Synthesis, and Experimental Confirmation. Molecules, 27.","DOI":"10.3390\/molecules27041234"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1080\/13543776.2020.1705783","article-title":"Factor XI(a) inhibitors for thrombosis: An updated patent review (2016-present)","volume":"30","year":"2020","journal-title":"Expert Opin. Ther. Pat"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1111\/j.1538-7836.2007.02500.x","article-title":"The central role of thrombin in hemostasis","volume":"5","author":"Crawley","year":"2007","journal-title":"J. Thromb. Haemost."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/35092573","article-title":"Role of thrombin signalling in platelets in haemostasis and thrombosis","volume":"413","author":"Sambrano","year":"2001","journal-title":"Nature"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"3672","DOI":"10.1002\/cmdc.202100431","article-title":"Microscale Parallel Synthesis of Acylated Aminotriazoles Enabling the Development of Factor XIIa and Thrombin Inhibitors","volume":"16","author":"Platte","year":"2021","journal-title":"Chemmedchem"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2350","DOI":"10.1021\/jm00068a012","article-title":"Characterization of the interaction between human alpha-thrombin and methyl 3-(2-methyl-1-oxopropoxy)[1]benzothieno[3,2-b]furan-2-carboxylate (LY806303) using electrospray mass spectrometry and tandem mass spectrometry","volume":"36","author":"Sall","year":"1993","journal-title":"J. Med. Chem."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Sivaraja, M., Pozzi, N., Rienzo, M., Lin, K., Shiau, T.P., Clemens, D.M., Igoudin, L., Zalicki, P., Chang, S.S., and Estiarte, M.A. (2018). Reversible covalent direct thrombin inhibitors. PLoS ONE, 13.","DOI":"10.1371\/journal.pone.0201377"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"13159","DOI":"10.1021\/acs.jmedchem.0c01635","article-title":"Acylated 1H-1,2,4-Triazol-5-amines Targeting Human Coagulation Factor XIIa and Thrombin: Conventional and Microscale Synthesis, Anticoagulant Properties, and Mechanism of Action","volume":"63","author":"Korff","year":"2020","journal-title":"J. Med. Chem."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/nrd3410","article-title":"The resurgence of covalent drugs","volume":"10","author":"Singh","year":"2011","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.thromres.2020.04.020","article-title":"VE-1902-A direct thrombin inhibitor with reversible covalent mechanism of action shows efficacy with reduced bleeding in rodent models of thrombosis","volume":"190","author":"Sivaraja","year":"2020","journal-title":"Thromb. Res."},{"key":"ref_20","unstructured":"Short, K.M., Pham, S.M., Williams, D.C., and Verseon Inc. USA (2014). Halogenopyrazoles as Inhibitors of Thrombin. (WO2014149139A2)."},{"key":"ref_21","unstructured":"Short, K.M., Estiarte-Martinez, M.A., Kita, D.B., Shiau, T.P., and Verseon Inc. USA (2016). Substituted Pyrazole Compounds as Serine Protease Inhibitors. (WO2016138532A1)."},{"key":"ref_22","unstructured":"Hirth, B.H., Janjigian, A., Vinick, F., and Genzyme Corp. USA (2002). Antibacterial Compounds. (U.S.6410533B1)."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"14475","DOI":"10.1021\/ja047472o","article-title":"Palladium- and copper-catalyzed synthesis of medium- and large-sized ring-fused dihydroazaphenanthrenes and 1,4-benzodiazepine-2,5-diones. control of reaction pathway by metal-switching","volume":"126","author":"Cuny","year":"2004","journal-title":"J. Am. Chem. Soc."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Kusakiewicz-Dawid, A., Porada, M., Dziuk, B., and Siodlak, D. (2019). Annular Tautomerism of 3(5)-Disubstituted-1H-pyrazoles with Ester and Amide Groups. Molecules, 24.","DOI":"10.3390\/molecules24142632"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2314","DOI":"10.1016\/j.tet.2019.03.003","article-title":"A new practical synthesis of 3-amino-substituted 5-aminopyrazoles and their tautomerism","volume":"75","author":"Lim","year":"2019","journal-title":"Tetrahedron"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1021\/jf010734a","article-title":"Acetylation of 5-amino-1H-[1,2,4]triazole revisited","volume":"50","author":"Dzygiel","year":"2002","journal-title":"J. Agric. Food Chem."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.ejmech.2008.03.017","article-title":"Design, synthesis and molecular modeling study of acylated 1,2,4-triazole-3-acetates with potential anti-inflammatory activity","volume":"44","author":"Alkaramany","year":"2009","journal-title":"Eur. J. Med. Chem."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1021\/jm00161a045","article-title":"3-(1H-tetrazol-5-yl)-4(3H)-quinazolinone sodium salt (MDL 427): A new antiallergic agent","volume":"29","author":"Peet","year":"1986","journal-title":"J. Med. Chem."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"4648","DOI":"10.1021\/ol1019713","article-title":"New synthesis of fluorinated pyrazoles","volume":"12","author":"Surmont","year":"2010","journal-title":"Org. Lett."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/1044-0305(90)85018-H","article-title":"Origin and Removal of Adducts (Molecular Mass = 98-U) Attached to Peptide and Protein Ions in Electrospray Ionization Mass-Spectra","volume":"1","author":"Chowdhury","year":"1990","journal-title":"J. Am. Soc. Mass. Spectr."},{"key":"ref_31","first-page":"A19503","article-title":"An Improved Potent Direct Thrombin Inhibitor Shows Efficacy with Low Bleeding Risk","volume":"136","author":"Datta","year":"2017","journal-title":"Circulation"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"9441","DOI":"10.1021\/jm4005835","article-title":"5-Chlorothiophene-2-carboxylic acid [(S)-2-[2-methyl-3-(2-oxopyrrolidin-1-yl)benzenesulfonylamino]-3-(4-methylpiperaz in-1-yl)-3-oxopropyl]amide (SAR107375), a selective and potent orally active dual thrombin and factor Xa inhibitor","volume":"56","author":"Meneyrol","year":"2013","journal-title":"J. Med. Chem."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"8563","DOI":"10.1021\/jm5010754","article-title":"How a beta-D-glucoside side chain enhances binding affinity to thrombin of inhibitors bearing 2-chlorothiophene as P1 moiety: Crystallography, fragment deconstruction study, and evaluation of antithrombotic properties","volume":"57","author":"Belviso","year":"2014","journal-title":"J. Med. Chem."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1021\/jm0203837","article-title":"Molecular structures of human factor Xa complexed with ketopiperazine inhibitors: Preference for a neutral group in the S1 pocket","volume":"46","author":"Maignan","year":"2003","journal-title":"J. Med. Chem."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"5900","DOI":"10.1021\/jm050101d","article-title":"Discovery of the novel antithrombotic agent 5-chloro-N-({(5S)-2-oxo-3-[4-(3-oxomorpholin-4-yl)phenyl]-1,3-oxazolidin-5-yl}methyl)thiophene-2-carboxamide (BAY 59-7939): An oral, direct factor Xa inhibitor","volume":"48","author":"Roehrig","year":"2005","journal-title":"J. Med. Chem."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"3559","DOI":"10.1038\/s41467-018-05769-2","article-title":"Intriguing role of water in protein-ligand binding studied by neutron crystallography on trypsin complexes","volume":"9","author":"Schiebel","year":"2018","journal-title":"Nat. Commun."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"257","DOI":"10.2174\/156802610790725506","article-title":"Entering the era of non-basic p1 site groups: Discovery of Xarelto (Rivaroxaban)","volume":"10","author":"Straub","year":"2010","journal-title":"Curr. Top. Med. Chem."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2769","DOI":"10.1021\/ct401110x","article-title":"Thermodynamics of Water in an Enzyme Active Site: Grid-Based Hydration Analysis of Coagulation Factor Xa","volume":"10","author":"Nguyen","year":"2014","journal-title":"J. Chem. Theory Comput."},{"key":"ref_39","unstructured":"(Bruker AXS (2021), 2021). Bruker AXS (2021), APEX4 Version 2021.4-0, SAINT Version 8.40B and SADABS Bruker AXS area detector scaling and absorption correction Version 2016\/2."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1107\/S2053273314026370","article-title":"SHELXT\u2014Integrated space-group and crystal-structure determination","volume":"71","author":"Sheldrick","year":"2015","journal-title":"Acta Cryst. A Found. Adv."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1107\/S2053229614024218","article-title":"Crystal structure refinement with SHELXL","volume":"71","author":"Sheldrick","year":"2015","journal-title":"Acta Cryst. C Struct. Chem."},{"key":"ref_42","unstructured":"(Bruker AXS (1998) XP\u2014Interactive Molecular Graphics, 1998). Bruker AXS (1998) XP\u2014Interactive Molecular Graphics, Version 5.1."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"9541","DOI":"10.1021\/acs.jmedchem.6b01291","article-title":"Novel Potent Proline-Based Metalloproteinase Inhibitors: Design, (Radio) Synthesis, and First in vivo Evaluation as Radiotracers for Positron Emission Tomography","volume":"59","author":"Kalinin","year":"2016","journal-title":"J. Med. Chem."}],"container-title":["Pharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1424-8247\/15\/11\/1340\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T01:05:18Z","timestamp":1760144718000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1424-8247\/15\/11\/1340"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,28]]},"references-count":43,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2022,11]]}},"alternative-id":["ph15111340"],"URL":"https:\/\/doi.org\/10.3390\/ph15111340","relation":{},"ISSN":["1424-8247"],"issn-type":[{"value":"1424-8247","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,28]]}}}